2010, Number 5
<< Back Next >>
Rev Mex Neuroci 2010; 11 (5)
Neurological paraneoplastic syndromes (Part III): Central nervous system, retinal, and spinal cord
Cacho-Díaz B, Herrera-Gómez Á, Luna-Ortiz K, Senties-Madrid H
Language: Spanish
References: 183
Page: 349-358
PDF size: 201.05 Kb.
ABSTRACT
The neurological paraneoplastic syndromes (NPS) of the central nervous system are the most frequently recognized in daily practice, in particular those considered as classical and include paraneoplastic cerebellar degeneration, limbic encephalitis, paraneoplastic encephalomyelitis and opsoclonusmyoclonus. NPS may also affect the spinal cord as in stiff-person syndrome, necrotizing myelopathy and motor or sensory neuronopathies. Paraneoplastic ocular syndromes are also seen by neurologists for we are sometimes the first to approach those patients i.e. cancer related retinopathy, melanoma associated retinopathy, optic neuritis. The main features of PNS are: a) Rapid onset and progression of symptoms (days to weeks); b) Abnormal cerebrospinal fluid in up to 95% of patients mainly lymphocytic pleocytosis; c) Abnormal magnetic resonance imaging since early stages, in particular abnormalities in FLAIR and T2 weight-images; d) Presence and synthesis of antineuronal antibodies in cerebrospinal fluid; and e) Association with cancer.
REFERENCES
Rosenfeld MR, Dalmau J. Update on paraneoplastic and autoimmune disorders of the central nervous system. Semin Neurol 2010; 30(3): 320-31.
Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008; 7(4): 327-40.
Psimaras D, Carpentier AF, Rossi C. Cerebrospinal fluid study in paraneoplastic syndromes. J Neurol Neurosurg Psychiatry 2010; 81(1): 42-5.
Cacho-Díaz B. Síndromes neurológicos paraneoplásicos (Parte I): Abordaje y características generales. Rev Mex Neuroci 2010; 11: 150-9.
Rauer S, Kaiser R. Demonstration of anti-HuD specific oligoclonal bands in the cerebrospinal fluid from patients with paraneoplastic neurological syndromes. Qualitative evidence of anti-HuD specific IgG-synthesis in the central nervous system. J Neuroimmunol 2000; 111(1-2): 241-4.
Stich O, Jarius S, Kleer B, Rasiah C, Voltz R, Rauer S. Specific antibody index in cerebrospinal fluid from patients with central and peripheral paraneoplastic neurological syndromes. J Neuroimmunol 2007; 183(1- 2): 220-4.
Abate G, Corazzelli G, Ciarmiello A, Monfardini S. Neurologic complications of Hodgkin’s disease: a case history. Ann Oncol 1997; 8(6): 593-600.
Plotkin SR, Wen PY. Neurologic complications of cancer therapy. Neurol Clin 2003; 21(1): 279-318, x.
Albert ML, Darnell RB. Paraneoplastic neurological degenerations: keys to tumor immunity. Nat Rev Cancer 2004; 4(1): 36-44.
Voltz R. Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. Lancet Neurol 2002; 1(5): 294-305.
Dalmau J, Gultekin HS, Posner JB. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol 1999; 9(2): 275-84.
Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004; 56(5): 715-9.
Wen PY, Schiff D. Neurologic complications of solid tumors. Neurol Clin 2003; 21(1): 107-40, viii.
Bataller L, Dalmau J. Paraneoplastic neurologic syndromes. Neurol Clin 2003; 21(1): 221-47, ix.
Elrington GM, Murray NM, Spiro SG, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry 1991; 54(9): 764-7.
Damek DM. Cerebral edema, altered mental status, seizures, acute stroke, leptomeningeal metastases, and paraneoplastic syndrome. Emerg Med Clin North Am 2009; 27(2): 209-29.
Heinemann S, Zabel P, Hauber H. Paraneoplastic syndromes in lung cancer. Cancer Therapy 2008; 6: 687-98.
Sacco E, Pinto F, Sasso F, Racioppi M, Gulino G, Volpe A, et al. Paraneoplastic syndromes in patients with urological malignancies. Urol Int 2009; 83(1): 1-11.
Recht L, Mrugala M. Neurologic complications of hematologic neoplasms. Neurol Clin 2003; 21(1): 87-105.
Blumenthal DT, Glenn MJ. Neurologic manifestations of hematologic disorders. Neurol Clin 2002; 20(1): 265-81, viii.
Petito CK, Gottlieb GJ, Dougherty JH, Petito FA. Neoplastic angioendotheliosis: ultrastructural study and review of the literature. Ann Neurol 1978; 3(5): 393-9.
Dalmau J. Recognizing paraneoplastic limbic encephalitis. J Clin Oncol 2009; 27(34): e230-1; author reply e2.
Anderson NE, Rosenblum MK, Posner JB. Paraneoplastic cerebellar degeneration: clinical-immunological correlations. Ann Neurol 1988; 24(4): 559-67.
O’Brien TJ, Pasaliaris B, D’Apice A, Byrne E. Anti-Yo positive paraneoplastic cerebellar degeneration: a report of three cases and review of the literature. J Clin Neurosci 1995; 2(4): 316-20.
Anderson NE, Posner JB, Sidtis JJ, Moeller JR, Strother SC, Dhawan V, et al. The metabolic anatomy of paraneoplastic cerebellar degeneration. Ann Neurol 1988; 23(6): 533-40.
Faris M, Abraham J, Barrett-Lee P. A patient with breast cancer and paraneoplastic cerebellar syndrome associated with anti-Purkinje cell antibodies: response to CMF chemotherapy. Clin Oncol (R Coll Radiol) 1998; 10(3): 202-3.
Furneaux HM, Rosenblum MK, Dalmau J, Wong E, Woodruff P, Graus F, et al. Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med 1990; 322(26): 1844-51.
Stark E, Wurster U, Patzold U, Sailer M, Haas J. Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. Arch Neurol 1995; 52(8): 814-8.
Greenlee JE, Clawson SA, Hill KE, Dechet CB, Carlson NG. Antineuronal autoantibodies in paraneoplastic cerebellar degeneration associated with adenocarcinoma of the prostate. J Neurol Sci 2010; 291(1-2): 74-8.
Hall DJ, Dyer ML, Parker JC, Jr. Ovarian cancer complicated by cerebellar degeneration: a paraneoplastic syndrome. Gynecol Oncol 1985; 21(2): 240-6.
Erez Y, Rojansky N, Shveiky D, Ben-Meir A, Benshushan A. Endometrial carcinoma first presenting as paraneoplastic cerebellar degeneration. Gynecol Oncol 2007; 105(3): 826-7.
Tanaka Y, Suzuki N, Takao M, Ichikawa A, Susumu N, Aoki D. Paraneoplastic cerebellar degeneration with fallopian tube adenocarcinoma. Gynecol Oncol 2005; 99(2): 500-3.
Marchand V, Graveleau J, Lanctin-García C, Bourbouloux E, Bridji B, Resche I, et al. A rare gynecological case of paraneoplastic cerebellar degeneration discovered by FDG-PET. Gynecol Oncol 2007; 105(2): 545-7.
Anderson NE, Rosenblum MK, Graus F, Wiley RG, Posner JB. Autoantibodies in paraneoplastic syndromes associated with small-cell lung cancer. Neurology 1988; 38(9): 1391-8.
Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 2000; 47(1): 9-17.
Mc Namara B, Boniface SJ, Ray J, Scolding NJ, Robertson N. Paraneoplastic sensory neuropathy and Purkinje cell antibodies. Muscle Nerve 1999; 22(10): 1466-7.
Minisini AM, Pauletto G, Bergonzi P, Fasola G. Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature. Breast Cancer Res Treat 2007; 105(2): 133-8.
De la Sayette V, Bertran F, Honnorat J, Schaeffer S, Iglesias S, Defer G. Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies: clinical response to excision of the primary tumor. Arch Neurol 1998; 55(3): 405-8.
Benarroch EE. Neuronal voltage-gated calcium channels: brief overview of their function and clinical implications in neurology. Neurology 2010; 74(16): 1310-5.
Leonovicz BM, Gordon EA, Wass CT. Paraneoplastic syndromes associated with lung cancer: a unique case of concomitant subacute cerebellar degeneration and Lambert-Eaton myasthenic syndrome. Anesth Analg 2001; 93(6):1557-9, table of contents.
Graus F, Lang B, Pozo-Rosich P, Saiz A, Casamitjana R, Vincent A. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 2002; 59(5): 764-6.
Mason WP, Graus F, Lang B, Honnorat J, Delattre JY, Valldeoriola F, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 1997; 120(Pt 8): 1279-300.
Moll JW, Henzen-Logmans SC, Van der Meche FG, Vecht CH. Early diagnosis and intravenous immune globulin therapy in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry 1993; 56(1): 112.
Monstad SE, Storstein A, Dorum A, Knudsen A, Lonning PE, Salvesen HB, et al. Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clin Exp Immunol 2006; 144(1): 53-8.
Dropcho EJ. Autoimmune central nervous system paraneoplastic disorders: mechanisms, diagnosis, and therapeutic options. Ann Neurol 1995; 37(Suppl. 1): S102-13.
Pinto A, Lang B. Paraneoplastic cerebellar degeneration and antibodies to P/Q-type calcium channels. Ann Neurol 2003; 54(2): 277, author reply-8.
Honnorat J, Aguera M, Guillon B, De Ferron E, Antoine JC, Dalmau J. Association of antineural autoantibodies in a patient with paraneoplastic cerebellar syndrome and small cell lung carcinoma. J Neurol Neurosurg Psychiatry 1997; 62(4): 425-6.
Graus F, Dalmau J, Valldeoriola F, Ferrer I, Rene R, Marin C, et al. Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin’s disease. J Neuroimmunol 1997; 74(1-2): 55-61.
Shams’ili S, Grefkens J, de Leeuw B, van den Bent M, Hooijkaas H, van der Holt B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003; 126(Pt 6): 1409-18.
Sutton I. Paraneoplastic neurological syndromes. Curr Opin Neurol 2002; 15(6): 685-90.
Pittock SJ, Lucchinetti CF, Parisi JE, Benarroch EE, Mokri B, Stephan CL, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 2005; 58(1): 96-107.
Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003; 53(5): 580-7.
Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymomarelated autoimmunity. Ann Neurol 2001; 49(2): 146-54.
Lang B, Dale RC, Vincent A. New autoantibody mediated disorders of the central nervous system. Curr Opin Neurol 2003; 16(3): 351-7.
Voltz R, Carpentier AF, Rosenfeld MR, Posner JB, Dalmau J. P/Q-type voltage-gated calcium channel antibodies in paraneoplastic disorders of the central nervous system. Muscle Nerve 1999; 22(1): 119-22.
Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998; 50(3): 652-7.
Choi KD, Kim JS, Park SH, Kim YK, Kim SE, Smitt PS. Cerebellar hypermetabolism in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry 2006; 77(4): 525-8.
Quinn N, Barnard RO, Kelly RE. Cerebellar syndrome in myxoedema revisited: a published case with carcinomatosis and multiple system atrophy at necropsy. J Neurol Neurosurg Psychiatry 1992; 55(7): 616-8.
Bataller L, Dalmau JO. Paraneoplastic disorders of the central nervous system: update on diagnostic criteria and treatment. Semin Neurol 2004; 24(4): 461-71.
Rojas I, Graus F, Keime-Guibert F, Rene R, Delattre JY, Ramon JM, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000; 55(5): 713-5.
Didelot A, Honnorat J. Update on paraneoplastic neurological syndromes. Curr Opin Oncol 2009; 21(6): 566-72.
Alamowitch S, Graus F, Uchuya M, Rene R, Bescansa E, Delattre JY. Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain 1997; 120(Pt 6): 923-8.
Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000; 123(Pt 7): 1481-94.
Dalmau J, Bataller L. Clinical and immunological diversity of limbic encephalitis: a model for paraneoplastic neurologic disorders. Hematol Oncol Clin North Am 2006; 20(6): 1319-35.
Rosenfeld MR, Dalmau J. Paraneoplastic limbic encephalitis associated with small-cell lung cancer. Community Oncology 2007; 4(8): 491-4.
Dropcho EJ. Remote neurologic manifestations of cancer. Neurol Clin 2002; 20(1): 85-122, vi.
Lawn ND, Westmoreland BF, Kiely MJ, Lennon VA, Vernino S. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc 2003; 78(11): 1363-8.
Rees JH. Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage. J Neurol Neurosurg Psychiatry 2004; 75(Suppl. 2): ii43-50.
Koide R, Shimizu T, Koike K, Dalmau J. EFA6A-like antibodies in paraneoplastic encephalitis associated with immature ovarian teratoma: a case report. J Neurooncol 2007; 81(1): 71-4.
Vincent A. Antibodies associated with paraneoplastic neurological disorders. Neurol Sci 2005; 26(Suppl. 1): S3-4.
Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127(Pt 8): 1831-44.
Rosenfeld MR, Eichen JG, Wade DF, Posner JB, Dalmau J. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 2001; 50(3): 339-48.
Waragai M, Chiba A, Uchibori A, Fukushima T, Anno M, Tanaka K. Anti-Ma2 associated paraneoplastic neurological syndrome presenting as encephalitis and progressive muscular atrophy. J Neurol Neurosurg Psychiatry 2006; 77(1): 111-3.
Tenner L, Einhorn L. Ma-2 paraneoplastic encephalitis in the presence of bilateral testicular cancer: diagnostic and therapeutic approach. J Clin Oncol 2009; 27(23): e57-8.
Van Altena AM, Wijnberg GJ, Kolwijck E, de Hullu JA, Massuger LF. A patient with bilateral immature ovarian teratoma presenting with paraneoplastic encephalitis. Gynecol Oncol 2008; 108(2): 445-8.
Foster AR, Caplan JP. Paraneoplastic limbic encephalitis. Psychosomatics 2009; 50(2): 108-13.
Rajappa S, Digumarti R, Immaneni SR, Parage M. Primary renal lymphoma presenting with paraneoplastic limbic encephalitis. J Clin Oncol 2007; 25(24): 3783-5.
Vernino S, Eggenberger ER, Rogers LR, Lennon VA. Paraneoplastic neurological autoimmunity associated with ANNA-1 autoantibody and thymoma. Neurology 2002; 59(6): 929-32.
Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol 2005; 58(4): 594-604.
Kararizou E, Markou I, Zalonis I, Gkiatas K, Triantafyllou N, Kararizos G, et al. Paraneoplastic limbic encephalitis presenting as acute viral encephalitis. J Neurooncol 2005; 75(2): 229-32.
Tonomura Y, Kataoka H, Hara Y, Takamure M, Naba I, Kitauti T, et al. Clinical analysis of paraneoplastic encephalitis associated with ovarian teratoma. J Neurooncol 2007; 84(3): 287-92.
Tormoehlen LM, Pascuzzi RM. Thymoma, myasthenia gravis, and other paraneoplastic syndromes. Hematol Oncol Clin North Am 2008; 22(3): 509-26.
Farrugia ME, Conway R, Simpson DJ, Kurian KM. Paraneoplastic limbic encephalitis. Clin Neurol Neurosurg 2005; 107(2): 128-31.
Scheid R, Honnorat J, Delmont E, Urbach H, Biniek R. A new antineuronal antibody in a case of paraneoplastic limbic encephalitis associated with breast cancer. J Neurol Neurosurg Psychiatry 2004; 75(2): 338-40.
Munshi SK, Thanvi B, Chin SK, Hubbard I, Fletcher A, Vallance TR. Paraneoplastic limbic encephalitis-case report and review of literature. Age Ageing 2005; 34(2): 190-3.
Honnorat J. Autoimmune limbic encephalitis: an expanding concept. Lancet Neurol 2010; 9(1): 24-5.
Ances BM, Vitaliani R, Taylor RA, Liebeskind DS, Voloschin A, Houghton DJ, et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 2005; 128(Pt 8): 1764-77.
Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004; 127(Pt 3): 701-12.
Honnorat J. Is autoimmune limbic encephalitis a channelopathy? Lancet Neurol 2010; 9(8): 753-5.
Buckley C, Oger J, Clover L, Tuzun E, Carpenter K, Jackson M, et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 2001; 50(1): 73-8.
Samarasekera SR, Vincent A, Welch JL, Jackson M, Nichols P, Griffiths TD. Course and outcome of acute limbic encephalitis with negative voltage-gated potassium channel antibodies. J Neurol Neurosurg Psychiatry 2007; 78(4): 391-4.
Tan KM, Lennon VA, Klein CJ, Boeve BF, Pittock SJ. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 2008; 70(20): 1883-90.
Kleopa KA, Elman LB, Lang B, Vincent A, Scherer SS. Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations. Brain 2006; 129(Pt 6): 1570-84.
Liguori R, Vincent A, Clover L, Avoni P, Plazzi G, Cortelli P, et al. Morvan’s syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 2001; 124(Pt 12): 2417-26.
Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterization of the antigen. Lancet Neurol 2010; 9(1): 67-76.
Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7(12): 1091-8.
Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61(1): 25-36.
Cacho-Díaz B, Estañol-Vidal B. Síndromes Neurológicos Paraneoplásicos (Parte II): Sistema nervioso periférico y autonómico. Rev Mex Neuroci 2010; 11: 226-33.
Graus F, Keime-Guibert F, Rene R, Benyahia B, Ribalta T, Ascaso C, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124(Pt 6): 1138-48.
Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu—associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine 1992; 71(2): 59-72.
Kleopa KA, Teener JW, Scherer SS, Galetta SL, Bird SJ. Chronic multiple paraneoplastic syndromes. Muscle Nerve 2000; 23(11): 1767-72.
Jardine DL, Krediet CP, Robinson BA. Baroreflex failure secondary to paraneoplastic encephalomyelitis in a 17 year old woman with neuroblastoma. J Neurol Neurosurg Psychiatry 2004; 75(11): 1650-1.
Simonelli M, Banna GL, Santoro A. Thymoma associated with myasthenia and autonomic anti-Hu paraneoplastic neuropathy. Tumori 2009; 95(2): 243-7.
Duff M, Dusenbery KE, Rodriguez FJ. Paraneoplastic encephalomyelitis: a case report and review of the literature. Gynecol Oncol 2006; 102(3): 593-5.
Tesseki K, Kataoka H, Terashima M, Kawahara M, Taoka T, Tanaka K, et al. Biphasic paraneoplastic brainstem encephalitis associated with anti-Ri antibody. J Neurooncol 2010.
Dalmau J, Furneaux HM, Cordon-Cardo C, Posner JB. The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol 1992; 141(4): 881-6.
Greenlee JE, Steffens JD, Clawson SA, Hill K, Dalmau J. Anti-Hu antibodies in Merkel cell carcinoma. Ann Neurol 2002; 52(1): 111-5.
Baloh RW, De Rossett SE, Cloughesy TF, Kuncl RW, Miller NR, Merrill J, et al. Novel brainstem syndrome associated with prostate carcinoma. Neurology 1993; 43(12): 2591-6.
Rizzardi G, Campione A, Scanagatta P, Terzi A. Paraneoplastic extra limbic encephalitis associated with thymoma. Interact Cardiovasc Thorac Surg 2009; 9(4): 755-6.
Vickers SM, Niederhuber JE. Hodgkin’s disease associated with neurologic paraneoplastic syndrome. South Med J 1997; 90(8): 839-44.
Pleasure D. Keeping “Trk” of paraneoplastic syndromes. Arch Neurol 2005; 62(10): 1508-9.
Shimamura M, Uchida Y, Terasaki T, Hashimoto Y, Yamasaki H, Tsuda H, et al. Hodgkin’s disease preceded by unique neurological symptoms. Intern Med 2001; 40(8): 819-21.
Voltz RD, Posner JB, Dalmau J, Graus F. Paraneoplastic encephalomyelitis: an update of the effects of the anti-Hu immune response on the nervous system and tumour. J Neurol Neurosurg Psychiatry 1997; 63(2): 133-6.
Nath U, Grant R. Neurological paraneoplastic syndromes. J Clin Pathol 1997; 50(12): 975-80.
Bataller L, Dalmau J. Paraneoplastic neurologic syndromes: approaches to diagnosis and treatment. Semin Neurol 2003; 23(2): 215-24.
Benyahia B, Liblau R, Merle-Beral H, Tourani JM, Dalmau J, Delattre JY. Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol 1999; 45(2): 162-7.
Manley GT, Smitt PS, Dalmau J, Posner JB. Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites. Ann Neurol 1995; 38(1): 102-10.
Dropcho EJ, King PH. Autoantibodies against the Hel-N1 RNA-binding protein among patients with lung carcinoma: an association with type I anti-neuronal nuclear antibodies. Ann Neurol 1994; 36(2): 200-5.
Honnorat J, Byk T, Kusters I, Aguera M, Ricard D, Rogemond V, et al. Ulip/CRMP proteins are recognized by autoantibodies in paraneoplastic neurological syndromes. Eur J Neurosci 1999; 11(12): 4226-32.
Llado A, Mannucci P, Carpentier AF, Paris S, Blanco Y, Saiz A, et al. Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes. Neurology 2004; 63(10): 1947-9.
Dalmau J, Posner JB. Neurologic paraneoplastic antibodies (anti-Yo; anti-Hu; anti-Ri): the case for a nomenclature based on antibody and antigen specificity. Neurology 1994; 44(12): 2241-6.
Graus F, Dalmou J, Rene R, Tora M, Malats N, Verschuuren JJ, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997; 15(8): 2866-72.
Dalmau J, Furneaux HM, Gralla RJ, Kris MG, Posner JB. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer—a quantitative western blot analysis. Ann Neurol 1990; 27(5): 544-52.
Allen JC, Rosen G. Transient cerebral dysfunction following chemotherapy for osteogenic sarcoma. Ann Neurol 1978; 3(5): 441-4.
Shavit YB, Graus F, Probst A, Rene R, Steck AJ. Epilepsia partialis continua: a new manifestation of anti-Hu-associated paraneoplastic encephalomyelitis. Ann Neurol 1999; 45(2): 255-8.
Bataller L, Rosenfeld MR, Graus F, Vilchez JJ, Cheung NK, Dalmau J. Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol 2003; 53(3): 347-53.
Turkel SB, Brumm VL, Mitchell WG, Tavare CJ. Mood and behavioral dysfunction with opsoclonus-myoclonus ataxia. J Neuropsychiatry Clin Neurosci 2006; 18(2): 239-41.
Wildhaber B, Niggli F, Bergstrasser E, Stallmach T, Sacher P. Paraneoplastic syndromes in ganglioneuroblastoma: contrasting symptoms of constipation and diarrhea. Eur J Pediatr 2003; 162(7-8): 511-3.
Mitchell WG, Dávalos-González Y, Brumm VL, Aller SK, Burger E, Turkel SB, et al. Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequel. Pediatrics 2002; 109(1): 86-98.
Lou E, Hensley ML, Lassman AB, Aghajanian C. Paraneoplastic opsoclonus-myoclonus syndrome secondary to immature ovarian teratoma. Gynecol Oncol 2010; 117(2): 382-4.
Bataller L, Graus F, Saiz A, Vilchez JJ. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001; 124(Pt 2): 437-43.
Musunuru K, Kesari S. Paraneoplastic opsoclonus-myoclonus ataxia associated with non-small-cell lung carcinoma. J Neurooncol 2008; 90(2): 213-6.
Pranzatelli MR, Tate ED, Wheeler A, Bass N, Gold AP, Griebel ML, et al. Screening for autoantibodies in children with opsoclonusmyoclonus- ataxia. Pediatr Neurol 2002; 27(5): 384-7.
Luque FA, Furneaux HM, Ferziger R, Rosenblum MK, Wray SH, Schold SC, Jr, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991; 29(3): 241-51.
Darnell RB. Paraneoplastic neurologic disorders: windows into neuronal function and tumor immunity. Arch Neurol 2004; 61(1): 30-2.
Kurian M, Lalive PH, Dalmau JO, Horvath J. Opsoclonus-myoclonus syndrome in anti-N-methyl-D-aspartate receptor encephalitis. Arch Neurol 2010; 67(1): 118-21.
Kuban KC, Ephros MA, Freeman RL, Laffell LB, Bresnan MJ. Syndrome of opsoclonus-myoclonus caused by Coxsackie B3 infection. Ann Neurol 1983; 13(1): 69-71.
Grant R, Graus F. Paraneoplastic movement disorders. Mov Disord 2009; 24(12): 1715-24.
Matsumoto L, Yamamoto T, Higashihara M, Sugimoto I, Kowa H, Shibahara J, et al. Severe hypokinesis caused by paraneoplastic anti- Ma2 encephalitis associated with bilateral intratubular germ-cell neoplasm of the testes. Mov Disord 2007; 22(5): 728-31.
Tremont-Lukats IW, Fuller GN, Ribalta T, Giglio P, Groves MD. Paraneoplastic chorea: case study with autopsy confirmation. Neuro Oncol 2002; 4(3): 192-5.
Sansing LH, Tuzun E, Ko MW, Baccon J, Lynch DR, Dalmau J. A patient with encephalitis associated with NMDA receptor antibodies. Nat Clin Pract Neurol 2007; 3(5): 291-6.
Grimaldi LM, Martino G, Braghi S, Quattrini A, Furlan R, Bosi E, et al. Heterogeneity of autoantibodies in stiff-man syndrome. Ann Neurol 1993; 34(1): 57-64.
Bacorro EA, Tehrani R. Stiff-person syndrome: persistent elevation of glutamic acid decarboxylase antibodies despite successful treatment with rituximab. J Clin Rheumatol 2010; 16(5): 237-9.
Butler MH, Hayashi A, Ohkoshi N, Villmann C, Becker CM, Feng G, et al. Autoimmunity to gephyrin in Stiff-Man syndrome. Neuron 2000; 26(2): 307-12.
Giometto B, Miotto D, Faresin F, Argentiero V, Scaravilli T, Tavolato B. Anti-gabaergic neuron autoantibodies in a patient with stiff-man syndrome and ataxia. J Neurol Sci 1996; 143(1-2): 57-9.
Mata S, Muscas GC, Cincotta M, Bartolozzi ML, Ambrosini S, Sorbi S. GAD antibodies associated neurological disorders: Incidence and phenotype distribution among neurological inflammatory diseases. J Neuroimmunol 2010.
Pittock SJ, Yoshikawa H, Ahlskog JE, Tisch SH, Benarroch EE, Kryzer TJ, et al. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc 2006; 81(9): 1207-14.
Sommer C, Weishaupt A, Brinkhoff J, Biko L, Wessig C, Gold R, et al. Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 2005; 365(9468): 1406-11.
Geis C, Beck M, Jablonka S, Weishaupt A, Toyka KV, Sendtner M, et al. Stiff person syndrome associated anti-amphiphysin antibodies reduce GABA associated [Ca(2+)]i rise in embryonic motoneurons. Neurobiol Dis 2009; 36(1): 191-9.
Murinson BB, Guarnaccia JB. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology 2008; 71(24): 1955-8.
David C, Solimena M, De Camilli P. Autoimmunity in stiff-Man syndrome with breast cancer is targeted to the C-terminal region of human amphiphysin, a protein similar to the yeast proteins, Rvs167 and Rvs161. FEBS Lett 1994; 351(1): 73-9.
Rosin L, DeCamilli P, Butler M, Solimena M, Schmitt HP, Morgenthaler N, et al. Stiff-man syndrome in a woman with breast cancer: an uncommon central nervous system paraneoplastic syndrome. Neurology 1998; 50(1): 94-8.
Folli F, Solimena M, Cofiell R, Austoni M, Tallini G, Fassetta G, et al. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 1993; 328(8): 546-51.
Floyd S, Butler MH, Cremona O, David C, Freyberg Z, Zhang X, et al. Expression of amphiphysin I, an autoantigen of paraneoplastic neurological syndromes, in breast cancer. Mol Med 1998; 4(1): 29-39.
De Camilli P, Thomas A, Cofiell R, Folli F, Lichte B, Piccolo G, et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J Exp Med 1993; 178(6): 2219-23.
Nayak L, Rubin M. Amphiphysin autoimmunity in paraneoplastic neurologic disease. Clin Adv Hematol Oncol 2009; 7(3): 183-4.
Dropcho EJ. Antiamphiphysin antibodies with small-cell lung carcinoma and paraneoplastic encephalomyelitis. Ann Neurol 1996; 39(5): 659-67.
Bouw J, Leendertse K, Tijssen MA, Dzoljic M. Stiff person syndrome and anesthesia: case report. Anesth Analg 2003; 97(2): 486-7, table of contents.
Dupond JL, Essalmi L, Gil H, Meaux-Ruault N, Hafsaoui C. Rituximab treatment of stiff-person syndrome in a patient with thymoma, diabetes mellitus and autoimmune thyroiditis. J Clin Neurosci 2010; 17(3): 389-91.
Essalmi L, Meaux-Ruault N, Hafsaoui C, Gil H, Curlier E, Dupond JL. [Stiff person syndrome associated with thymoma. Efficacy of thymectomy]. Rev Med Interne 2007; 28(9): 627-30.
Gutmann B, Crivellaro C, Mitterer M, Zingerle H, Egarter-Vigl E, Wiedermann CJ. Paraneoplastic stiff-person syndrome, heterotopic soft tissue ossification and gonarthritis in a HLA B27-positive woman preceding the diagnosis of Hodgkin’s lymphoma. Haematologica 2006; 91(Suppl.12): ECR59.
Lorish TR, Thorsteinsson G, Howard FM, Jr. Stiff-man syndrome updated. Mayo Clin Proc 1989; 64(6): 629-36.
Graber JJ, Nolan CP. Myelopathies in patients with cancer. Arch Neurol 2010; 67(3): 298-304.
Behl D, Hendrickson AW, Moynihan TJ. Oncologic emergencies. Crit Care Clin 2010; 26(1): 181-205.
Blade J, Rosinol L. Complications of multiple myeloma. Hematol Oncol Clin North Am 2007; 21(6): 1231-46, xi.
Virani S, Tan M, Abraham J. Transverse myelitis: amphiphysin autoimmunity paraneoplastic syndrome in a woman with breast cancer. Clin Adv Hematol Oncol 2009; 7(3): 180-2.
Vernino S. Paraneoplastic disorders affecting the neuromuscular junction or anterior horn cell. Continuum lifelong learning in neurology 2009; 15(1): 132-46.
Vincent A, Drachman DB. Amyotrophic lateral sclerosis and antibodies to voltage-gated calcium channels-new doubts. Ann Neurol 1996; 40(5): 691-3.
Keegan BM, Pittock SJ, Lennon VA. Autoimmune myelopathy associated with collapsin response-mediator protein-5 immunoglobulin G. Ann Neurol 2008; 63(4): 531-4.
Falah M, Schiff D, Burns TM. Neuromuscular complications of cancer diagnosis and treatment. J Support Oncol 2005; 3(4): 271-82.
Forsyth PA, Dalmau J, Graus F, Cwik V, Rosenblum MK, Posner JB. Motor neuron syndromes in cancer patients. Ann Neurol 1997; 41(6): 722-30.
Rudnicki SA, Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve, and muscle. Muscle Nerve 2000; 23(12): 1800-18.
Younger DS. Motor neuron disease and malignancy. Muscle Nerve 2000; 23(5): 658-60.
Rowland LP. Paraneoplastic primary lateral sclerosis and amyotrophic lateral sclerosis. Ann Neurol 1997; 41(6): 703-5.
Ko MW, Dalmau J, Galetta SL. Neuro-ophthalmologic manifestations of paraneoplastic syndromes. J Neuroophthalmol 2008; 28(1): 58-68.
Bataller L, Dalmau J. Neuro-ophthalmology and paraneoplastic syndromes. Curr Opin Neurol 2004; 17(1): 3-8.
Kloos L, Sillevis Smitt P, Ang CW, Kruit W, Stoter G. Paraneoplastic ophthalmoplegia and subacute motor axonal neuropathy associated with anti-GQ1b antibodies in a patient with malignant melanoma. J Neurol Neurosurg Psychiatry 2003; 74(4): 507-9.
Ohmer R, Golnik KC, Richards AI, Kosmorsky GS. Ophthalmoplegia associated with the anti-Ri antibody. J Neuroophthalmol 1999; 19(4): 246-8.
Kim H, Lim Y, Kim KK. Anti-ri-antibody-associated paraneoplastic syndrome in a man with breast cancer showing a reversible pontine lesion on MRI. J Clin Neurol 2009; 5(3): 151-2.
Hammam T, McFadzean RM, Ironside JW. Anti-hu paraneoplastic syndrome presenting as bilateral sixth cranial nerve palsies. J Neuroophthalmol 2005; 25(2): 101-4.
Damek DM. Paraneoplastic Retinopathy/Optic Neuropathy. Curr Treat Options Neurol 2005; 7(1): 57-67.
Kondo M, Mokuno K, Uemura A, Kachi S, Nakamura M, Kondo A, et al. Paraneoplastic retinopathy associated with retroperitoneal liposarcoma. Clin Ophthalmol 2010; 4: 243-5.
Cross SA, Salomao DR, Parisi JE, Kryzer TJ, Bradley EA, Mines JA, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003; 54(1): 38-50.
Full text